中证智能财讯 华检医疗（01931）4月30日披露2024年度报告。报告期内，公司实现营业总收入31.84亿元，同比增长2.14%；归母净利润2.6亿元，同比增长 9.35%；经营活动产生的现金流量净额为1.4亿元，同比下降52.03%；据报告显示，华检医疗基本每股收益为0.1742元，加权平均净资产收益率为7.3%。 以4月30日收盘价计算，华检医疗目前市盈率（TTM）约10.12倍，市净率（TTM）约0.71倍，市销率（TTM）约0.83倍。 市盈率(TTM)历史分位(%) 001 900 91-24 87c56 80 78:29 70 6645 60 57,98 50 50-99 40 30 20 -20-82 11692 10 0 2019-12-37 1 1-12-37 2n- 制图数据来自恒生聚源数据库 市净率(LF)历史分位(%) (100 90 92g35 86.53 85-21 80 75079 70 60 50 49.6 ad 40 30 29o73 20 1967 10 0 2019-12-37 I 1-12-37 2n- 制图数据来自恒生聚源数据库 华检医疗控股有限公司是一家投资控股公 ...

Financial Performance - The company reported revenue of RMB 3,162,415,000 for the year ended December 31, 2024, representing a growth of 2.4% compared to RMB 3,088,387,000 in 2023[9]. - Net profit for the year increased by 12.2% to RMB 266,034,000, up from RMB 237,126,000 in the previous year, primarily due to improved gross margins in the analysis instruments and after-sales service business[9]. - Adjusted net profit for the year was RMB 280,413,000, reflecting a growth of RMB 18,289,000 or 7.0% compared to RMB 262,124,000 in 2023[13]. - The adjusted profit attributable to the company's owners increased by 4.2% to RMB 274,246,000 from RMB 263,161,000 in the previous year[13]. - The gross profit margin for the year improved, contributing to the overall profit growth[9]. - Gross profit increased to RMB 751,173,000, reflecting an 11.8% growth from RMB 671,701,000 in 2023[50]. - The gross margin improved from 21.7% in 2023 to 23.8% in 2024, primarily due to reduced costs in analysis instruments and services[71]. - After-sales service revenue increased by 14.8% to RMB 205,989,000 from RMB 179,374,000 in 2023[63]. - Distribution business revenue was RMB 2,946,782,000, accounting for 93.2% of total revenue, with a growth of 1.7% compared to RMB 2,898,390,000 in 2023[63]. Market and Strategic Initiatives - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[24]. - The company has expanded its "Hua Jian Ecosystem" product portfolio and partnership network, collaborating with 20 local IVD manufacturers and 6 international leading IVD companies, covering over 500 diagnostic products[14]. - The company plans to enhance its distribution network and hospital coverage while expanding its product portfolio through collaboration with global IVD manufacturers[24]. - The company is focusing on research and development in mass spectrometry reagents through equity acquisitions or capital increases in non-wholly owned subsidiaries[14]. - The company aims to expand its product portfolio and distribution network to capture high growth potential in the IVD market[42]. - The group is actively seeking companies specializing in AI robotics solutions to support the future deployment of AI technology[26]. - The group aims to accelerate AI technology research and application, focusing on medical data analysis and automated testing processes[25]. Operational Developments - The group has installed a total of 6,763 Sysmex Corporation coagulation analyzers in hospitals and medical institutions as of December 31, 2024[20]. - As of December 31, 2024, the company has installed 101 Hemostasis immunoassay analyzers utilizing four types of thrombus markers in Chinese hospitals and medical institutions[33]. - The company has established a distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 351 direct customers and 1,253 distributors[35]. - The company is committed to maintaining high environmental and social standards to ensure sustainable business development[153]. Financial Position and Assets - Total assets increased by 15.4% to RMB 5,523,884,000 from RMB 4,785,052,000[52]. - Cash and cash equivalents rose by 44.9% to RMB 1,774,358,000 compared to RMB 1,224,786,000 in 2023[52]. - The group's net current assets increased significantly to RMB 2,169,969,000, compared to RMB 386,878,000 as of December 31, 2023[91]. - The asset-liability ratio as of December 31, 2024, was 13.3%, an increase from 6.7% as of December 31, 2023[101]. Shareholder and Governance Matters - The board has resolved not to recommend a final dividend for the reporting period, compared to a final dividend of 6.209 HKD cents per share in the previous year[104]. - The company has a diverse shareholder base with multiple entities holding over 5% of the shares[185]. - The ownership structure indicates a concentration of control among a few major shareholders, which may impact corporate governance[188]. - The company has confirmed compliance with non-competition agreements during the reporting period, as reviewed by independent non-executive directors[177]. Employee and Management Information - Employee compensation expenses totaled RMB 221,693,000 during the reporting period, up from RMB 183,869,000 in the previous year[105]. - The group emphasizes employee training and development, investing resources in continuous education and training programs[148]. - The company has established a mandatory provident fund retirement benefits plan for its Hong Kong employees, with contributions based on a percentage of employees' basic salaries[171]. Risks and Challenges - The group faces intense competition in the Chinese IVD product distribution industry due to government policies encouraging large distributors to acquire smaller ones[144]. - The board is aware of the need to monitor competitive conditions and take appropriate measures[145].

Financial Performance - The company reported revenue of RMB 3,162,415,000 for the year ended December 31, 2024, representing a growth of 2.4% compared to RMB 3,088,387,000 in 2023[6] - Gross profit increased by 11.8% to RMB 751,173,000 from RMB 671,701,000 year-on-year[5] - Net profit for the year rose by 12.2% to RMB 266,034,000, up from RMB 237,126,000 in the previous year[6] - Adjusted net profit attributable to the owners of the parent company was RMB 274,246,000, a 4.2% increase from RMB 263,161,000[5] - Total revenue for the year ended December 31, 2024, was RMB 3,162,415 thousand, an increase from RMB 3,088,387 thousand in 2023, representing a growth of approximately 2.4%[22] - Revenue from mainland China accounted for RMB 3,154,904 thousand, up from RMB 3,075,304 thousand in the previous year, indicating a growth of about 2.6%[22] - Revenue from other regions decreased to RMB 7,511 thousand in 2024 from RMB 13,083 thousand in 2023, reflecting a decline of approximately 42.5%[22] - Revenue from sales of trade goods was RMB 2,946,782 thousand, up from RMB 2,898,390 thousand, reflecting a growth of 1.7%[25] - The pre-tax profit for 2024 was RMB 260,420 thousand, an increase from RMB 238,163 thousand in 2023[36] - Total tax expenses for 2024 amounted to RMB 135,743 thousand, up from RMB 102,203 thousand in 2023, representing a 33.0% increase[29] - Adjusted profit under non-GAAP for the year was RMB 280,413,000, an increase of RMB 18,289,000 or 7.0% compared to the same period in 2023[55] - EBITDA was RMB 475,956,000, up 19.6% from RMB 397,928,000[65] - The gross margin improved to 23.8%, up 2.1 percentage points from 21.7%[65] - The net profit margin increased to 8.4%, up 0.7 percentage points from 7.7%[65] Assets and Liabilities - The total assets less current liabilities amounted to RMB 3,977,215,000, compared to RMB 3,585,930,000 in 2023[10] - Cash and cash equivalents increased to RMB 1,774,358,000 from RMB 1,224,786,000, indicating improved liquidity[10] - Inventory levels rose to RMB 1,236,751,000, up from RMB 1,109,554,000, reflecting increased stock[10] - The company’s total equity increased to RMB 3,761,186,000 from RMB 3,385,889,000 year-on-year[11] - The company’s financing costs rose to RMB 35,979,000 from RMB 21,040,000, indicating higher borrowing costs[8] - Non-current assets totaled RMB 1,776,170 thousand as of December 31, 2024, slightly increasing from RMB 1,770,653 thousand in 2023[23] - The group's net current assets increased to RMB 2,169,969,000 as of December 31, 2024, compared to RMB 386,878,000 as of December 31, 2023[90] - The group's debt-to-asset ratio as of December 31, 2024, was 13.3%, compared to 6.7% as of December 31, 2023[100] Dividends and Shareholder Information - The company did not recommend the distribution of a final dividend for the fiscal year 2024[7] - The company did not propose any dividends for the year ending December 31, 2024[31] - The board has resolved not to recommend a final dividend for the reporting period, compared to a previous dividend of HKD 0.06209 per share[102] Operational Highlights - The company installed 6,763 Hemostasis analyzers in hospitals and medical institutions across China as of December 31, 2024[43] - The company has a distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 351 direct customers and 1,253 distributors[45] - The company aims to expand its product portfolio and distribution network to capture high growth potential in the IVD market[50] - Plans to enhance hospital solution services through data-driven operational models and automation tools to improve efficiency[51] - The company will increase R&D investment focusing on mass spectrometry, molecular diagnostics, and microbiology[52] Research and Development - Research and development costs for 2024 were RMB 7,402 thousand, a decrease from RMB 8,665 thousand in 2023, indicating a reduction of 14.6%[27] - The company received government subsidies totaling RMB 15,524 thousand in 2024, slightly down from RMB 15,996 thousand in 2023[25] Corporate Governance - Ernst & Young resigned as the company's auditor on October 28, 2024, and Daxin Ma Shi Yun Certified Public Accountants was appointed as the new auditor from the same date[107] - The board composition changed during the reporting period, with several new appointments and resignations of directors, effective from various dates in 2024[109] - The company has complied with the public float requirement, maintaining at least 25% of its issued share capital held by the public throughout the reporting period[118] - The company has adopted the standard code of conduct for securities transactions by directors as per the listing rules[115] - The company confirmed that all directors complied with the standard code of conduct throughout the reporting period[116] Market Outlook - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate of 15.7% from 2021 to 2027[48] - The company is closely monitoring AI technology advancements and their potential impact on the industry landscape[49] - The establishment of Goheal Technology Limited in Hong Kong marks the company's entry into the AI sector, aiming for scalable deployment of AI technologies[53] - The company is actively exploring cross-industry technology synergies to develop forward-looking technological capabilities[54] Miscellaneous - The company completed a placement of 270,918,016 shares at HKD 0.7 per share, raising approximately RMB 173,142,000[41] - The total capital expenditure during the reporting period was RMB 67,103,000, primarily for the procurement of properties, plants, and equipment[96] - The total employee compensation expenses amounted to RMB 221,693,000 during the reporting period, an increase from RMB 183,869,000 in the previous year[103] - The company has not engaged in any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[114] - The company announced that its shares were suspended from trading on April 1, 2025, and it has applied to resume trading on April 14, 2025[121] - The company will publish its annual report and notice of the annual general meeting in accordance with the listing rules[120]

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 1,353,470,000, a decrease of 1.7% compared to RMB 1,377,314,000 in the same period of 2023[5] - The gross profit for the same period increased by 7.7% to RMB 324,692,000, up from RMB 301,540,000 in 2023[5] - The net profit for the period rose by 22.7% to RMB 127,566,000, compared to RMB 104,002,000 in the previous year[6] - Profit attributable to equity holders of the parent increased by 21.6% to RMB 125,288,000 from RMB 103,009,000[5] - The adjusted profit for the period, a non-GAAP measure, was RMB 127,790,000, reflecting an 8.9% increase from RMB 117,396,000 in 2023[6] - Basic and diluted earnings per share for the period were RMB 9.27, up from RMB 7.62, representing an increase of 1.65[5] - The company reported an operating loss of RMB 5,012,000 from its proprietary brand product business, which is still in the early research stage, but this loss did not significantly impact overall financial performance[11] - The gross profit margin improved to 24.0%, up by 2.1 percentage points from 21.9% in the previous year[18] - The net profit for the reporting period was RMB 127,566,000, a 22.7% increase from RMB 104,002,000 for the six months ended June 30, 2023, mainly due to the increase in after-sales service gross profit margin[39] - The adjusted net profit for the reporting period was RMB 127,790,000, an increase of 8.9% from RMB 117,396,000 in the previous period, also driven by the increase in after-sales service gross profit margin[40] Revenue Breakdown - Distribution business revenue was RMB 1,253,634,000, accounting for 92.7% of total revenue, down 3.0% from RMB 1,293,002,000[22] - Revenue from solution services provided to clinical laboratories in hospitals reached RMB 117,462,000, a 4.7% increase from RMB 112,227,000 for the six months ended June 30, 2023[9] - Revenue from the sale of medical consumables was RMB 1,170,596,000, an increase of 1.2% from RMB 1,156,622,000 in the previous year[83] - Revenue from after-sales services increased significantly to RMB 95,258,000, up 22% from RMB 78,163,000 in the prior year[83] - Revenue from sales to hospitals and medical institutions was RMB 188,124,000, an increase from RMB 171,061,000 in the previous year[83] Market Position and Strategy - The company is a leading distributor of IVD products in China and is involved in the research, development, production, and sales of its own brand IVD products[7] - The company aims to stabilize and increase market share and profitability through a competitive and diversified product portfolio and extensive distribution network[7] - The company continues to focus on expanding its market presence and enhancing its product offerings in the IVD sector[7] - The company plans to expand its product portfolio and distribution network to capture high growth potential in the IVD market[14] - The company aims to enhance its R&D capabilities by investing in equipment and hiring experts to develop proprietary IVD products[16] Assets and Liabilities - Cash and cash equivalents increased by 29.8% to RMB 1,589,593,000 compared to RMB 1,224,786,000 at the end of 2023[19] - The total assets of the company rose by 11.3% to RMB 5,328,067,000 from RMB 4,785,052,000[19] - The net current assets increased to RMB 1,829,422,000 as of June 30, 2024, compared to RMB 1,783,091,000 as of December 31, 2023, reflecting an increase of RMB 46,331,000[45] - The group's debt-to-asset ratio was approximately 15.0% as of June 30, 2024, significantly up from 6.7% as of December 31, 2023[54] - The total liabilities as of June 30, 2024, were RMB 259,617,000, a decrease from RMB 330,790,000 as of December 31, 2023, reflecting a reduction of approximately 21.5%[95] Shareholder Information - The total issued and paid-up share capital is 1,354,590,080 shares, with a par value of USD 0.0005 per share, equivalent to RMB 4,637,000[97] - The company has a total of 175,517,429 shares held by KS&KL Investment Co. Limited, representing 12.96% of the issued shares[106] - The company’s major shareholder, King Sun Limited, also holds 175,517,429 shares, accounting for 12.96% of the issued shares[108] - The total shares held by the directors and major executives amount to 465,185,899 shares collectively[107] - The company’s shareholding structure indicates significant control by a few major shareholders, which may impact future strategic decisions[108] Employee Stock Option Plan - The employee stock option plan allows for the issuance of up to 32,507,627 shares, representing 5% of the total issued shares at the time, aimed at attracting and retaining top talent[117] - The management of the employee stock option plan is vested in the board or a committee authorized by the board, ensuring compliance with applicable laws and company regulations[118] - The total number of unexercised stock options as of the interim report date is 19,504,576, representing approximately 0.96% of the total issued shares[128] - The stock option plan is effective for ten years from July 12, 2019, unless terminated earlier by the shareholders or the board[132] - The employee stock option plan is designed to reward employees and promote the overall success of the group, aligning employee interests with company performance[116] Corporate Governance - The company has complied with all applicable corporate governance code provisions except for the separation of the roles of Chairman and CEO[146] - The audit committee reviewed the interim report and found the financial statements to be prepared in accordance with applicable accounting standards[148] - The board composition has changed with several new appointments and resignations during the reporting period[151][152] - The company has adopted a standard code for securities transactions by directors, and all directors confirmed compliance during the reporting period[145] Future Outlook - The Chinese IVD market is projected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[12] - The company is actively exploring business cooperation opportunities, including technology exchanges, to enhance its market competitiveness[16] - The company signed a strategic cooperation agreement with Sysmex in 2023 to deepen collaboration and revise distribution rights, transitioning to long-term distribution rights in specific regions[8]

Financial Performance - The company reported revenue of RMB 1,353,470,000 for the six months ended June 30, 2024, a decrease of 1.7% compared to RMB 1,377,314,000 in the same period of 2023[2]. - Profit for the period increased by 22.7% to RMB 127,566,000, up from RMB 104,002,000 in the previous year, primarily due to an increase in the gross margin of after-sales service[2]. - Adjusted profit attributable to the owners of the parent company was RMB 125,288,000, representing a 21.6% increase from RMB 103,009,000 in the prior year[3]. - Basic and diluted earnings per share increased to RMB 9.27 from RMB 7.62, reflecting a growth of 21.6%[6]. - Total comprehensive income for the period was RMB 127,758,000, compared to RMB 118,288,000 in the same period last year[5]. - Gross profit increased to RMB 324,692,000, representing a growth of 7.7% from RMB 301,540,000 in the previous year[39]. - Net profit for the period was RMB 127,566,000, an increase of 22.7% compared to RMB 104,002,000 in the same period last year[39]. - Adjusted net profit rose to RMB 127,790,000, reflecting an 8.9% increase from RMB 117,396,000 in the prior year[39]. - The gross margin improved to 24.0%, up 2.1 percentage points from 21.9%[38]. - The net profit margin increased to 9.4%, up 1.8 percentage points from 7.6%[38]. Revenue Breakdown - Revenue from the sale of medical equipment was RMB 87,616,000, down 38.6% from RMB 142,529,000 in the previous year[17]. - Revenue from the sale of medical consumables increased to RMB 1,170,596,000, up 1.2% from RMB 1,156,622,000 in the prior year[17]. - Revenue from after-sales services rose to RMB 95,258,000, an increase of 22% compared to RMB 78,163,000 in the previous year[17]. - Revenue from government subsidies was RMB 6,775,000, significantly higher than RMB 3,720,000 in the previous year, reflecting a 82.5% increase[18]. - Distribution business revenue accounted for 92.7% of total revenue, while after-sales service revenue increased by 21.9% to RMB 95,258,000, representing 7.0% of total revenue[44]. - The revenue from IVD analysis instruments in the distribution business decreased by 38.2% to RMB 87,032,000, while IVD reagents and other consumables revenue increased by 1.2% to RMB 1,170,596,000[45]. Assets and Liabilities - The company's total assets as of June 30, 2024, amounted to RMB 5,171,489,000, an increase from RMB 5,085,920,000 as of December 31, 2023[7]. - Current assets increased to RMB 3,522,083,000 from RMB 2,982,213,000, indicating a growth of 18.1%[7]. - The company's net asset value rose to RMB 3,436,885,000, up from RMB 3,385,889,000, reflecting a growth of 1.5%[8]. - Non-current liabilities decreased slightly to RMB 198,521,000 from RMB 200,041,000, showing a reduction of 0.8%[8]. - Non-current assets totaled RMB 1,766,561,000 as of June 30, 2024, slightly down from RMB 1,770,653,000 as of December 31, 2023[15]. - The debt-to-asset ratio as of June 30, 2024, was approximately 15.0%, an increase from 6.7% as of December 31, 2023[71]. Operational Highlights - The company continues to focus on enhancing its after-sales service business, which has contributed positively to its profit margins[2]. - The group has installed approximately 6,723 Sysmex coagulation analyzers in hospitals and medical institutions in China as of June 30, 2024[30]. - The group has a distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 234 direct customers and 950 distributors as of June 30, 2024[31]. - The group incurred an operating loss of RMB 5,012,000 from its proprietary brand product development projects, which had no significant impact on overall financial performance[33]. - The company has established a joint venture with Carbon Cloud Intelligent for the development of molecular diagnostic reagents[33]. Employee and Governance - As of June 30, 2024, the group had a total of 815 employees, an increase from 779 employees as of June 30, 2023[74]. - Total employee compensation expenses amounted to RMB 66,402,000 for the reporting period, compared to RMB 62,898,000 for the six months ended June 30, 2023, reflecting an increase of approximately 8%[74]. - The company has adopted a competitive compensation system based on performance, with employees eligible for year-end bonuses and stock rewards[74]. - The board of directors has undergone changes, with new appointments and resignations during the reporting period[76]. - The company confirms compliance with the corporate governance code, with a clear division of responsibilities between the chairman and the CEO[77]. Future Outlook - The company plans to expand its product portfolio and distribution network to capture high growth potential in the IVD market[36]. - The company aims to enhance its R&D capabilities and accelerate the expansion of its proprietary brand product customer base, including AI-related projects[37]. - The Chinese IVD market is projected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[34].

Financial Performance - The company's total revenue for the year ended December 31, 2023, was RMB 3,088,387 thousand, an increase of 12.4% compared to RMB 2,748,809 thousand in 2022[21] - Net profit for the year grew by 21.3%, primarily due to increased revenue and the absence of certain expenses related to employee compensation and asset impairments that were present in the previous year[10] - Basic and diluted earnings per share for the year were RMB 17.62, compared to RMB 15.61 and RMB 15.50 in the previous year, respectively, reflecting a significant increase[3] - The company's total comprehensive income for the year was RMB 237,193 thousand, slightly down from RMB 237,615 thousand in 2022[3] - The adjusted net profit under non-GAAP was RMB 262,124,000, reflecting a 17.0% increase from RMB 224,052,000 in the previous year[63] - The group's profit before tax increased by 21.3% to RMB 237,126,000 compared to RMB 195,530,000 for the previous year[171] - The adjusted profit for the year was RMB 262,124,000, an increase of 17.0% compared to RMB 224,052,000 for the year ended December 31, 2022, primarily due to increased demand for IVD products as hospital operations gradually returned to normal post-COVID-19[176] Revenue Sources - Revenue from solution services provided to seven Chinese tertiary hospitals reached RMB 241,944,000, up 17.8% from RMB 205,406,000 in the previous year[39] - The distribution business generated revenue of RMB 2,898,390,000, accounting for 93.9% of total revenue, with a growth of 12.5% compared to the previous year[79] - Revenue from self-branded products in mainland China for the year 2023 was RMB 1,765,767 thousand, compared to RMB 1,769,320 thousand in 2022, indicating a decrease of about -0.3%[128] Financial Stability - Non-current liabilities decreased to RMB 200,041 thousand from RMB 215,649 thousand in the previous year, indicating improved financial stability[4] - The net asset value of the company increased to RMB 3,385,889 thousand from RMB 3,153,464 thousand in the previous year, showcasing growth in shareholder equity[4] - Total assets increased by 10.9% to RMB 4,785,052,000 from RMB 4,314,277,000, and equity attributable to owners of the parent rose by 6.1% to RMB 3,344,935,000 from RMB 3,153,386,000[71] - The debt-to-equity ratio remained stable at 0.1, indicating a consistent leverage position[71] - The debt-to-asset ratio as of December 31, 2023, was approximately 6.7%, down from 7.6% as of December 31, 2022[200] Cost Management - Financing costs decreased to RMB 21,040 thousand from RMB 30,580 thousand in the previous year, reflecting better cost management[22] - The cost of sales for the period was RMB 2,416,686,000, up 12.9% from RMB 2,140,668,000 for the year ended December 31, 2022, mainly due to increased sales[81] - The gross profit margin for the reporting period was 21.7%, a decrease of 0.4 percentage points compared to the previous year[60] - The gross profit margin for the period was 21.7%, a decrease from 22.1% for the year ended December 31, 2022, attributed to lower sales prices of IVD analyzers and increased service costs[89] Operational Insights - The company continues to focus on the sales and manufacturing of medical equipment and consumables, along with providing after-sales services, indicating a stable business model[26] - The company has established a distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 332 direct customers and 1,164 distributors as of December 31, 2023[52] - The company aims to expand its product portfolio and distribution network to capture the high growth potential of the IVD market[61] - The company plans to enhance its R&D capabilities and accelerate the expansion of its proprietary brand product customer base[58] - The company intends to hire more sales personnel to manage the promotion and marketing of its solution services[57] Market Trends - The IVD market in China is projected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[50] - The coagulation analysis IVD market in China was valued at RMB 5 billion in 2021, with the top three market participants holding a combined market share of 77.7%[54] Employee and Administrative Expenses - The total employee benefit expenses, including salaries and wages, amounted to RMB 183,869 thousand, compared to RMB 177,517 thousand in the previous year, showing an increase of approximately 3.5%[132] - Administrative expenses rose by 4.6% to RMB 159,980,000 from RMB 152,917,000, primarily due to increased business activities as COVID-19 impacts diminished[167] Cash Flow and Liquidity - Cash and cash equivalents increased by 20.0% to RMB 1,224,786,000 from RMB 1,020,626,000[71] - Cash and cash equivalents increased to RMB 1,224,786,000 from RMB 1,020,626,000, indicating improved liquidity[101] - Trade receivables at the end of the reporting period amounted to RMB 532,158,000, a decrease from RMB 566,796,000 in the previous year[142] Research and Development - Research and development costs for the year were RMB 8,665 thousand, up from RMB 7,219 thousand in 2022, reflecting an increase of about 20%[132] - The company plans to enhance its R&D capabilities by investing in equipment and hiring experts, focusing on developing proprietary IVD products with market potential[92] Dividends - The company proposed a final dividend of HKD 0.06209 per share, subject to approval at the upcoming annual general meeting[99] - The proposed final dividend for the year is HKD 6.209 per share, an increase from HKD 5.556 per share in the previous year, representing an increase of approximately 11.7%[134]

Revenue and Profitability - The company's revenue for the reporting period was RMB 1,377,314,000, an increase of 17.1% compared to RMB 1,176,557,000 for the six months ended June 30, 2022, primarily due to increased demand for IVD products as hospital operations gradually returned to normal post-COVID-19[1] - Distribution business revenue reached RMB 1,293,002,000, accounting for 93.9% of total revenue, with a year-on-year increase of 17.8% from RMB 1,097,468,000[3] - The self-branded product business saw a significant increase of 241.0%, with revenue rising to RMB 6,149,000 from RMB 1,803,000[3] - The company's gross profit was RMB 301,540,000, representing a 13.2% increase from RMB 266,423,000 for the same period last year[17] - The group's net profit for the period was RMB 104,002,000, a 49.2% increase from RMB 69,701,000 in the previous year[37] - Adjusted net profit for the period was RMB 117,396,000, reflecting a 21.3% increase from RMB 96,773,000 year-on-year[38] - Profit attributable to equity holders of the parent company rose by 26.9% to RMB 103,009,000 from RMB 81,149,000[159] - The EBITDA for the period was RMB 191,864,000, representing a significant increase of 41.7% compared to RMB 135,442,000 in the prior year[186] Cost and Expenses - The gross profit margin for the reporting period was 21.9%, a decrease from 22.6% for the six months ended June 30, 2022, mainly due to increased service costs[22] - Sales costs increased by 18.2% to RMB 1,075,774,000 from RMB 910,134,000 in the previous year[11] - Sales and distribution expenses rose by 31.7% to RMB 60,568,000, attributed to increased marketing activities following the easing of COVID-19 impacts[29] - Administrative expenses decreased by 7.1% to RMB 71,933,000, primarily due to the absence of share-based payment expenses that occurred in the previous year[31] Cash Flow and Financial Position - As of June 30, 2023, the group's cash and cash equivalents amounted to RMB 1,248,799,000, up from RMB 1,020,626,000 at the end of 2022[42] - The total equity attributable to the company's owners was RMB 3,202,848,000, an increase from RMB 3,153,386,000 at the end of 2022[43] - The company recorded a net cash inflow from operating activities of RMB 131,125,000, a significant improvement compared to a net outflow of RMB 100,554,000 in the same period last year[123] - The company's debt-to-asset ratio was approximately 10.9% as of June 30, 2023, compared to 7.6% as of December 31, 2022[57] - The total liabilities decreased to RMB 216,741,000, indicating a stable financial position[115] Market and Business Development - The company plans to continue expanding its market presence and investing in new product development to meet growing customer demand[1] - The company plans to continue expanding its distribution business and improving distribution channels[73] - The company aims to enhance its customer base under the expanded distribution business, with an investment of RMB 52,400,000[73] - The group established a distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 240 direct customers and 935 distributors as of June 30, 2023[167] - The company aims to enhance its R&D capabilities by investing in equipment and hiring experts, focusing on developing proprietary IVD products with market potential[182] Foreign Exchange and Other Income - Other income and gains increased by 1,276.7% to RMB 18,957,000, primarily due to an increase in foreign exchange gains[27] - The company recorded a net foreign exchange gain of RMB 12,730,000 during the reporting period, compared to a net foreign exchange loss of RMB 2,232,000 for the six months ended June 30, 2022[1] - The company experienced a foreign exchange loss of RMB 531,000, compared to a loss of RMB 2,795,000 in the same period last year[131] Inventory and Receivables - The company’s inventory increased to RMB 822,814,000 from RMB 628,622,000, indicating a rise of approximately 31%[112] - Trade receivables decreased to RMB 491,036,000 from RMB 566,796,000, a decline of about 13.3%[112] Future Outlook - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate of 15.7% from 2021 to 2027[175] - The compound annual growth rate (CAGR) for the Chinese coagulation analysis IVD first-level distribution market is projected to increase from 13.3% to 17.5% from 2021 to 2027, with expected sales revenue reaching RMB 15.7 billion by 2027[178]

財務摘要 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 華檢醫療控股有限公司（「本公司」）董事（「董事」，各自為「董事」）會（「董事會」） 謹此宣佈本公司及其附屬公司（此後統稱「本集團」）截至二零二三年六月三十日止 六個月（「報告期間」）的未經審核綜合中期業績，其已經本公司審核委員會（「審核 委員會」）審閱及已經董事會於二零二三年八月十八日核准。本集團於報告期間的 財務摘要連同二零二二年同期的比較數字載列如下： 收益 毛利 期內溢利 母公司擁有人應佔溢利 期內經調整溢利 （非公認會計原則，見附註） 母公司擁有人應佔經調整溢利 （非公認會計原則，見附註） 每股盈利 基本（人民幣分） 攤薄（人民幣分） 於報告期間，本集團實現收益人民幣1,377,314,000元，較二零二二年同期增加 17.1%。有關增加主要是由於終端客戶對體外診斷（「IVD」）產品的需求增加，這 是由於醫院的營運在新型冠狀病毒疫情（「COVID-19」）過後逐步恢復正常。 附註：期內經調整溢利及母公司擁有人應佔經調整溢利為非公認會計原則財務計量，並按期內 ...

Business Expansion and Market Presence - The company has expanded its product portfolio under the "Hua Jian Ecosystem" project to cover over 500 products from 18 local IVD manufacturers and 6 foreign manufacturers[15]. - As of December 31, 2022, the company had 295 direct customers and 1,139 distributors, covering 1,599 tertiary hospitals in China[25]. - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[29]. - The company aims to expand its distribution network and hospital coverage as part of its business strategy in China[30]. - The company is expanding its market presence in D regions, aiming to capture E% of the market share by the end of the next fiscal year[74]. - The company aims to provide solutions for at least two new hospitals in 2023 to capitalize on market trends and opportunities[130]. - The product portfolio includes over 500 products from 18 local IVD manufacturers with independent intellectual property rights and 6 well-known foreign IVD manufacturers[128]. - The company has established strategic partnerships with renowned IVD manufacturers to enhance its product offerings and expand its distribution network[128]. Financial Performance - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[74]. - The group achieved revenue of RMB 2,748,809,000, representing a growth of 0.7% compared to the previous year[159]. - The company reported revenue of RMB 2,748,809,000 for the year ended December 31, 2022, an increase of 0.7% compared to RMB 2,730,670,000 in 2021[180]. - Net profit for the year increased by 20.9% to RMB 195,530,000, driven by an increase in gross margin and a reduction in employee compensation expenses related to the share incentive plan[181]. - Adjusted net profit for the year was RMB 224,052,000, representing a growth of 12.0% compared to RMB 200,048,000 in the previous year[186]. - The adjusted net profit attributable to the company's shareholders rose by 11.1% to RMB 228,504,000 from RMB 205,706,000 in 2021[186]. - Basic earnings per share increased to RMB 15.61 from RMB 13.19, while diluted earnings per share rose to RMB 15.50 from RMB 12.94[180]. - The board proposed a final dividend of RMB 66,206,000, equating to HKD 0.05556 per share, in recognition of the support from shareholders[35]. - The company proposed a final dividend of HKD 0.05556 per share for the year ended December 31, 2022[182]. Research and Development - The company plans to enhance its R&D capabilities through internal growth and acquisitions, focusing on mass spectrometry and microbiology analysis[34]. - Research and development expenditures increased by H%, reflecting the company's commitment to innovation and product development[74]. - The company has been actively seeking investment opportunities in high-tech and innovative local IVD manufacturers to expand its ecosystem[15]. Environmental Sustainability - The company aims to enhance its environmental sustainability by implementing energy-saving measures and reducing greenhouse gas emissions[184]. - The total greenhouse gas emissions (Scope 1 and 2) amounted to 965.93 tons of CO2 equivalent, an increase from 858.35 tons in the previous year[164]. - Direct greenhouse gas emissions (Scope 1) increased to 620.22 tons of CO2 equivalent from 526.45 tons in the previous year[164]. - Energy indirect greenhouse gas emissions (Scope 2) were reported at 345.71 tons of CO2 equivalent, up from 331.90 tons in the previous year[164]. - The total amount of harmless waste per million RMB of revenue decreased by approximately 50% compared to the previous year, reflecting improved employee awareness of waste reduction[192]. - Energy consumption density increased by approximately 2.17% compared to the previous year, primarily due to the recovery of business activities involving vehicle usage[198]. - The group is actively seeking opportunities to implement environmental measures to improve its environmental performance[156]. - The group has established internal control mechanisms to enhance environmental awareness among employees and comply with relevant laws and regulations[156]. Corporate Governance - The Group has complied with all disclosure requirements under the Listing Rules regarding related party transactions[45]. - The Board of Directors has confirmed compliance with the corporate governance code throughout the reporting period[55]. - The Group's audit committee reviewed the unaudited interim financial statements for the six months ending June 30, 2022[70]. - The audit committee is responsible for reviewing the Group's financial information and discussing accounting policies and practices with management and external auditors[71]. - The Group has established four board committees to oversee specific areas of governance[66]. - The Group's non-executive directors serve a term of three years, with the possibility of reappointment[61]. - The Group has implemented a framework for high-level corporate governance to protect shareholder interests and enhance corporate value[54]. - The Group has engaged Ernst & Young as its auditor to report on related party transactions in accordance with the Listing Rules[45]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, targeting a G% reduction in costs over the next year[74]. - Employee compensation expenses related to the share incentive plan decreased significantly from RMB 38,555,000 in 2021 to RMB 11,993,000 in the reporting period[181]. - The Group paid approximately RMB 3,664,000 in actual rent to the Xinhua Medical Group during the reporting period for properties leased in Shanghai and Jinan[43]. - The rental agreements are short-term leases with a duration not exceeding one year, involving fixed amounts plus utilities and management fees[43].

截至二零二二年十二月三十一日，本集團並無持有其他公司的任何股權重大投資。 未來重大投資事項及資本資產計劃 截至二零二二年十二月三十一日，本集團並無任何資本承擔（截至二零二一年十 二月三十一日：無）以收購物業、廠房或設備。 截至二零二二年十二月三十一日，除本公司日期為二零一九年六月二十九日之招 股章程（「招股章程」）「未來計劃及所得款項用途」一節所披露的計劃資本開支外， 本集團並無有關重大投資事項及資本資產的其他計劃。除本公司首次公開發售所 得款項淨額外，還將通過內部產生現金、外部借款以及不時從資本市場籌集的其 他資金滿足資金需求。 購股權計劃 為吸引及挽留更多適合本集團發展的人才，本集團已採納首次公開發售前購股權 計劃（「僱員購股權計劃」，於二零一七年十二月二十九日獲批准並於二零一九年 三月二十七日作出進一步修訂）及購股權計劃（「購股權計劃」，於二零一九年六月 32 二十一日獲批准，詳情載於招股章程）。自採納之日起直至本公告日期，本集團已 分別根據僱員購股權計劃及購股權計劃授出32,507,627份及26,668,000份購股權； 截至二零二二年十二月三十一日，根據僱員購股權計劃及購股權計劃13,003,05 ...